Small Business - Americus Times-Recorder | Americus Times-Recorder
Jacobio Pharma announced Nature Medicine publication of glecirasib's pivotal phase II trial data for KRAS G12C mutant NSCLC, showing 47.9% response rate, 8.2 months median progression-free survival, and 13.6 months median overall survival. Glecirasib has a manageable safety profile and is under NMPA China's Priority Review.
Reference News
Small Business - Americus Times-Recorder | Americus Times-Recorder
Jacobio Pharma announced Nature Medicine publication of glecirasib's pivotal phase II trial data for KRAS G12C mutant NSCLC, showing 47.9% response rate, 8.2 months median progression-free survival, and 13.6 months median overall survival. Glecirasib has a manageable safety profile and is under NMPA China's Priority Review.